EUCTR2006-006946-32-GB进行中（未招募）1 期
A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function
AstraZeneca AB, European Regulatory Affairs0 个研究点目标入组 112 人开始时间: 2007年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •For inclusion in the study patients must fulfil all of the following criteria:
- •1. Provision of written informed consent (by patient or appropriate designee according to local regulations)
- •2. Documented stable CAD fulfilling any of the following, and taking 75-100mg ASA daily treatment:
- •- Stable angina pectoris with objective evidence of CAD
- •- Previous MI history
- •- Previous revascularization history, (i.e., PCI or coronary artery bypass graft [CABG])
- •3. Aged 18 years or older, male or female
- •4. Females of childbearing potential (i.e., females who are not post-menopausal or surgically sterile) must:
- •- have a negative urine or blood pregnancy test at enrolment and prior to randomisation at Visit 2
- •- currently be using a hormonal contraceptive and agree to continue its use in addition to using double-barrier local contraception (i.e., intra-uterine device plus spermicidal and condom for male partner) from screening through study completion.
- •For inclusion in the genetic research, patients must sign the informed consent for genetic research.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any of the following is regarded as a criterion for exclusion from the study:
- •1. Any indication (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve, coronary stent) for antithrombotic treatment (e.g., warfarin, clopidogrel, ASA dose other than 75 to 100 mg daily) during study period
- •2. Concomitant therapy with moderate or strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers within 14 days of study treatment. For example:
- •- Moderate inhibitors: Amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, verapamil
- •- Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir.
- •- Substrates with narrow therapeutic index: cyclosporine, quinidine.
- •- Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine.
- •The sponsor should be consulted for enrollment with any concomitant medicines which are suspected of undergoing moderate/strong drug-drug interaction
- •3. Increased bleeding risk including:
- •- Recent (within 30 days) GI bleeding
- •- Any history of intracranial, intraocular, retroperitoneal, or spinal bleeding
- •- Recent (within 30 days of dosing) major trauma
- •- Sustained uncontrolled hypertension (systolic blood pressure [SBP]>180mmHg or diastolic blood pressure [DBP]>100mmHg)
- •- History of hemorrhagic disorders that can increase the risk of bleeding, e.g., haemophilia, von Willebrand’s disease.
- •- Inability to discontinue required concomitant therapy with non-selective non steroidal anti inflammatory drug (NSAID) at screening
- •- Patients that have recently used (within 30 days of screening) any oral or parenteral antithrombotic agents (Section 3.7), with the exception of clopidogrel and ASA
- •- Platelet count less than 100,000 mm3 or hemoglobin <10 g/dL
- •4. History of congestive heart failure, chronic obstructive pulmonary disease, chronic or active asthma, interstitial lung disease”, other known pulmonary disease that will influence the cardiopulmonary function test interpretation
- •5. Diabetic patients with HbA1c=10%
- •6. Contraindication or other reason that clopidogrel, ASA, or AZD6140 should not be administered (e.g., hypersensitivity, active bleeding, major surgery within 30 days of dosing, any bleeding tendency [coagulation defects], acute or chronic liver disease etc.)
- •7. History of drug addiction or alcohol abuse in the previous 2 years
- •8. Patient requires dialysis or has a creatinine clearance <30mL/min as calculated by the Cockcroft-Gault equation:
- •(140-age) x WT
- •Creatinine clearance = --------------------------------- (x 0.85 for females)
- •72 x serum creatinine
- •where WT is weight in kg,
- •serum creatinine is in mg/dL
- •9. Participation in another investigational drug or device study within 30 days of dosing
- •10. Recent (within 30 days of dosing) blood donation
- •11. Women who are pregnant or lactating
- •12. Patients that are scheduled for revascularization (
研究者
相似试验
进行中（未招募）
不适用
A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for PONV - N/AEUCTR2004-001021-22-FIGlaxoSmithKline Research and Development Limited624
已完成
3 期
To Evaluate the Efficacy and Safety of Etifoxine in Comparison to Alprazolam for the Treatment of Adult Patients with Generalized Anxiety Disorder (a condition of excessive worry about everyday situations) with Somatic Symptoms (an extreme focus on physical symptoms such as pain or fatigue)CTRI/2023/01/048875Sun Pharma Laboratories Limited (SPLL)260
已完成
不适用
A clinical study to determine bioequivalence, safety and tolerability of drug called Tiotropium Bromide Inhalation PowderCTRI/2022/01/039634Phargentis SA296
进行中（未招募）
不适用
A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects with MalignanciesEUCTR2005-002552-17-HUSosei R&D Ltd150
进行中（未招募）
不适用
A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.EUCTR2004-005032-35-DKAlizyme Therapeutics Limited890